Skip to content
ApprovedFDA approved

Cabergoline (Dostinex)

Prescription prolactin-lowering medicine that bodybuilders also use; long-term use can damage the heart valves.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Cabergoline (Dostinex) vial

DETAILED OVERVIEW

What is Cabergoline (Dostinex)?

Cabergoline (Dostinex) is a long-acting prescription medicine that imitates the action of dopamine and lowers the production of the hormone prolactin. It has been approved in Europe since 1992 for treating excess prolactin and the pituitary tumors that cause it, and is registered in Hungary and Poland as well. Bodybuilders also use it off-label alongside certain steroids, against complaints caused by raised prolactin.

Side effects include nausea, dizziness and a drop in blood pressure on standing. It can cause compulsive gambling or shopping, hypersexuality and sudden falling asleep. If it pushes prolactin too low, loss of sex drive, low mood and lasting tiredness can follow. Mainly with long-term use, damage to the heart valves and scarring of the lungs, the lining of the chest and the abdominal cavity can occur. It is contraindicated in pregnancy and breastfeeding, because it blocks milk production and can restart ovulation.

Mechanism

Long-acting ergot D2 DA agonist, pituitary lactotroph prolactin suppression

Half-life

~63-69 hours (very long)

Onset

Prolactin reduction measurable 3 h, plateau 48-72 h

Legal status

EMA + FDA Rx, HU + PL approved, WADA allowed (not listed)

Data console

Lab data

Androgenic:AnabolicN/A (not AAS)
AR bindingD2 Ki ~0.4 nM (high affinity), D1 ~85× lower.…
Active half-life~63-69 hours (parent compound active, major metabolites inactive)
Detection windowNot relevant (WADA not listed).
AromatizationNone – DA agonist, not steroid mechanism.
HepatotoxicityLow hepatic; rare cardiac valvulopathy at high dose (>3 mg/week) chronic (Parkinson's protocol doses) – at AAS-used 0.5-1 mg/week dose, clinically NO documented risk (FDA Dostinex label).

Safety

Side effects, stop signs, contraindications

Side effects · 7

  • Nausea, vomiting and gastrointestinal upset, mainly with the first doses; reduced by taking it after food and titrating slowly.
  • Orthostatic (postural) hypotension, dizziness and faintness, especially at the start of dosing or on standing up.
  • Headache, fatigue and somnolence; rarely sudden sleep onset, so driving and operating machinery require caution.
  • Impulse-control disorders (pathological gambling, hypersexuality, compulsive shopping or eating) – a dopamine-agonist class effect, rarer with cabergoline but documented.
  • Cardiac valve damage (regurgitation, fibrotic change) – an ergot-derived, 5-HT2B-mediated class effect, mainly with prolonged high (Parkinson-level) doses; rare at AAS doses, but annual echocardiography is warranted with chronic use.
  • Overdosing or too-aggressive titration can push prolactin below normal, causing low libido, low mood and persistent fatigue ('prolactin crash').
  • Pulmonary, pleural and retroperitoneal fibrosis (connective-tissue scarring) – a rare, dose- and duration-dependent ergot-alkaloid effect with chronic use.

Contraindications · 7

  • Pre-existing cardiac valve disease or previously documented valvular fibrosis/regurgitation – an ergot-derived agent is contraindicated here.
  • Ergot-alkaloid hypersensitivity or allergy (e.g. cross-reactivity with bromocriptine, methysergide).
  • Pregnancy and breastfeeding: cabergoline suppresses lactation and may restore ovulation; in planned pregnancy use only under supervision, and consider contraception.
  • Uncontrolled severe hypertension or hypertensive disorders of pregnancy (preeclampsia/eclampsia) – increased blood-pressure and vasospasm risk.
  • Concurrent D2-antagonist antipsychotic therapy (haloperidol, risperidone, olanzapine) – mechanistic conflict, the effects cancel each other.
  • Severe hepatic impairment – reduced CYP3A4 metabolism leads to higher drug levels and increased side-effect risk.
  • History of pulmonary, pleural or retroperitoneal fibrosis – ergot agents can worsen it.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about Cabergoline (Dostinex)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.